EU Public–Private

Europe’s Innovation Engine: How Public–Private Partnerships Are Transforming Biomedical Research

David Alvaro, Ph.D.

Pharma's Almanac

Insulin

Project Insulin: Rebuilding Insulin Access for Patients, Not Profit

David Alvaro, Ph.D.; Eric Moyal

Pharma's Almanac

Health Equity

How is the pharmaceutical industry addressing global health inequities?

Pharma's Almanac

LGBTQ+ Equality

Empowering LGBTQ+ Voices in Life Sciences: A Conversation with OUTbio Greater New York

Heath R. Ingram

OUTbio: Greater New York

War on Science

Chilling New Attacks on Scientific Integrity

David Alvaro, Ph.D.

Pharma's Almanac

NIH

The White House’s War on the NIH and the Disasters Ahead

David Alvaro, Ph.D.

Pharma's Almanac

Collaboration

Three Decades of Collaboration: Evolution from Basic Partnerships to Complex Open-Innovation Models

Cynthia A. Challener, Ph.D.

Pharma's Almanac

NIH Funding

NIH Funding Cuts Put Innovation, Health Equity, and Lives at Risk

David Alvaro, Ph.D.

Pharma's Almanac

Synthetic Biology

Leaps and Bounds for Synthetic Biology Startups

Macquarie University

Research

Translating Academic Pursuits into Real-World Applications

Macquarie University

Synthetic Biology

Queensland University of Technology's Cutting-Edge Synthetic Biology Lab

Queensland University of Technology (QUT)

Partnerships

University-Industry Partnerships Tackling Genetic Disease Therapies and Diagnostic Innovation

Avicena Systems

Biosensors

The Partnerships Powering Next-Gen Oncology Care

Olivia Newton-John Cancer Research Institute

CRISPR

The Groundbreaking Potential of CRISPR Gene Editing

Olivia Newton-John Cancer Research Institute

Melanoma

Understanding the Challenges in Tackling Melanoma and Other Forms of Cancer

Olivia Newton-John Cancer Research Institute

Oncology

Up Close and Personal with Scientists on the Cutting Edge of Melanoma Research

Olivia Newton-John Cancer Research Institute